

Table S1 Primer sequence

Primer name	sequence (5' → 3')
CYP2E1	Forward Primer CGTTGCCTTGCTTGTCTGGA
	Reverse Primer AAGAAAGGAATTGGGAAAGGTCC
Keap1	Forward Primer TGCCCCTGTGGTCAAAGTG
	Reverse Primer GGTTCGGTTACCGTCCTGC
Nrf2	Forward Primer CAACCCGAAGCACGCTGAAGG
	Reverse Primer GGACGCTCGGCTGGGACTC
SOD2	Forward Primer CAGACCTGCCTTACGACTATGG
	Reverse Primer CTCGGTGGCGTTGAGATTGTT
Sab	Forward Primer GCCTGGAGAGGATCTCAGATG
	Reverse Primer TCAGACGGACTCGTCGGTC
BCL-X	Forward Primer GACAAGGAGATGCAGGTATTGG
	Reverse Primer TCCCGTAGAGATCCACAAAAGT
Bax	Forward Primer TGAAGACAGGGGCCTTTTTG
	Reverse Primer AATTCGCCGGAGACACTCG

Table S2 Antibody used for Western Blot

Antibody	From
CYP2E1	Abcam ab28146
Nrf-2	Abcam ab62352
JNK	Abcam ab179461
p-JNK	Abcam ab124956
AKS1	Abcam ab45178
p-ASK1	Gene Tex GTX50229
MKK4	Abcam ab33912
p-MKK4	Abcam ab52958
Keap-1	Cell Signalling D6B12
Caspase	Abcam ab179517
eNOS	Cell Signalling 9572S
HO-1	Cell Signalling 70081S
Bcl-XL	Abcam ab32370
Bax	Abcam ab182733
GAPDH	Cell Signalling 2118S

Table S3 Effects of different concentrations of COST and COSM on cell viability

C(mg/mL)	0	0.25	0.5	1	2	4	6
Cell viability (%) (COST)	100% ±5.62%	99.83%± 4.36%	99.19%± 6.21%	97.59%± 8.10%	90.24%± 5.11%	69.75%± 6.32%	53.27%± 3.52%
Cell viability (%) (COSM)	100%± 8.18%	98.71%± 5.47%	97.67%± 17.00%	95.19%± 13.39%	92.53%± 7.68%	87.86%± 2.34%	56.39%± 6.12%

Table S4 Effects of COST and COSM on cell viability of APAP-induced hepatocyte injury

Groups	CON	APAP	APAP+ COST- L	APAP+ COST- M	APAP+ COST- H	APAP+ COSM- L	APAP+ COSM- M	APAP+ COSM- H
Cell viability (%)	100.00± 10.74	46.86± 8.69	52.81± 4.70	72.78± 13.05**	83.51± 13.54**	44.64± 9.29	70.60± 8.57**	80.30± 9.25**

Notes: vs. APAP group, * $p < 0.05$, ** $p < 0.01$




Figure S1. Effect of different modeling concentrations (APAP) and time on cell viability rate (A) and IC₅₀ curve (B); The effects of COST and COSM on the growth status of hepatocyte L02 treated with APAP (8mM) for 12h were observed by microscope (C) (200X).